Corrigendum to "When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma." [Crit. Rev. Oncol. Hematol. 2026 May:221:105238.].
- DOI
- 10.1016/j.critrevonc.2026.105632
- Published
- 2026 Nov
- Container
- Critical reviews in oncology/hematology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105632,
title = {Corrigendum to "When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma." [Crit. Rev. Oncol. Hematol. 2026 May:221:105238.].},
author = {Buti S and Dalla Valle B and Acunzo A and Tuttobene P and Tamarozzi P and Agnetti V and Maffezzoli M},
year = {2026},
journal = {Critical reviews in oncology/hematology},
doi = {10.1016/j.critrevonc.2026.105632},
url = {https://doi.org/10.1016/j.critrevonc.2026.105632}
}RIS
TY - JOUR TI - Corrigendum to "When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma." [Crit. Rev. Oncol. Hematol. 2026 May:221:105238.]. AU - Buti S AU - Dalla Valle B AU - Acunzo A AU - Tuttobene P AU - Tamarozzi P AU - Agnetti V AU - Maffezzoli M PY - 2026 JO - Critical reviews in oncology/hematology DO - 10.1016/j.critrevonc.2026.105632 UR - https://doi.org/10.1016/j.critrevonc.2026.105632 ER -
APA
S, B., B, D. V., A, A., P, T., P, T., V, A., & M, M. (2026). Corrigendum to "When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma." [Crit. Rev. Oncol. Hematol. 2026 May:221:105238.].. Critical reviews in oncology/hematology. https://doi.org/10.1016/j.critrevonc.2026.105632
Source records
- pubmed · retrieved 2026-11-10T13:12:00.772Z
- europe-pmc · retrieved 2026-11-10T13:12:00.781Z